Imagabalin

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameImagabalin
Drug Alias Name伊玛巴林imagabalineimagabalina胺甲辛酸imagabalinum +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsAnxiety DisordersRenal InsufficiencyKidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsAnxiety DisordersRenal InsufficiencyKidney Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG